Virtual Posters for the 2019 CDCN Meeting @ ASH

On December 7th 2019, 70 Castleman disease experts met in Orlando for the CDCN Working Dinner at ASH

Researchers from all over the globe are working hard to defeat Castleman disease

Every year, the CDCN hosts a Working Dinner during the Annual American Society of Hematology (ASH) meeting, the largest international hematology meeting in the world. This year, we are highlighting important research from physicians and researchers around the world who help battle Castleman disease. Check out the virtual posters below!

Evaluation of Japanese and international diagnostic criteria for iMCD

Idiopathic multicentric Castleman disease (iMCD) is difficult to diagnose due to its rarity, wide-range of symptoms and disease severity, and its similarity in signs and symptoms to other autoimmune diseases and cancers. This research and work by CDCN Scientific Advisory Board member Dr. Makoto Ide helps continue the development of diagnosis algorithms for iMCD.

Virtual Poster

More about Dr. Makoto Ide

Dr. Makoto Ide, the chief director of Hematology at Takamatsu Red Cross Hospital and a physician scientist with over 20 years treating Castleman disease, is conducting research to test and improve our diagnostic guidelines for idiopathic multicentric Castleman disease (iMCD). See a few of his Castleman disease publications below:

Fujimoto, Shino, Tomohiro Koga, Atsushi Kawakami, Hiroshi Kawabata, Shinichiro Okamoto, Masao Mizuki, Shingo Yano et al. “Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.” Modern rheumatology 28, no. 1 (2018): 161-167.
Ide, Makoto, Yasunori Kawachi, Yoichiro Izumi, Kanji Kasagi, and Tetsuro Ogino. “Long‐term remission in HIV‐negative patients with multicentric Castleman’s disease using rituximab.” European journal of haematology 76, no. 2 (2006): 119-123.
Suda, Tetsuji, Harutaka Katano, Georges Delsol, Chihiro Kakiuchi, Tomoko Nakamura, Mami Shiota, Tetsutaro Sata, Masaki Higashihara, and Shigeo Mori. “HHV‐8 infection status of AIDS‐unrelated and AIDS‐associated multicentric Castleman’s disease.” Pathology international 51, no. 9 (2001): 671-679.

Single-Cell Analysis of PBMCs in iMCD identifies a Type I interferon response associated with increased mTOR activation

Researchers at University of Pennsylvania are working hard to identify potential pathophysiological mechanisms and cellular drivers of iMCD TAFRO. Ruth Anne Langan Pai was recently awarded one of the 2019 ASH Achievement awards for her presentation on Single-Cell Analysis of PBMCs in idiopathic multicentric Castleman disease identifies a Type I interferon response associated with increased mTOR activation”. The award and her research was recently highlighted by the Check Rare organization.

Virtual Poster

Increased mTOR activation in iMCD

Researchers at the University of Pennsylvania’s CSTL are working on research that characterizes mTOR activation in different subtypes of Castleman disease. To learn more about the mTOR project and other projects, check out the CDCN research pipeline, the CSTL research descriptions, and the abstract presented at the International Myeloma Workshop.

Virtual Poster

Researchers at Penn present statistical analysis on the most frequently used treatments in a real-world cohort of iMCD patients

Virtual Poster